These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8259153)

  • 21. [Principles, methods and criteria for assessing the effectiveness of potentially cardiotonic compounds at the preclinical research stage].
    Chekman IS; Tkachuk VV
    Farmakol Toksikol; 1984; 47(6):5-15. PubMed ID: 6394358
    [No Abstract]   [Full Text] [Related]  

  • 22. Infusion therapy in severe heart failure. A reappraisal.
    Campana C; Scelsi L; Serio A
    Ital Heart J; 2003 May; 4 Suppl 2():15S-21S. PubMed ID: 14635365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphodiesterase inhibitors: haemodynamic effects related to the treatment of cardiac failure.
    Hillis WS; Been M
    Eur Heart J; 1982 Dec; 3 Suppl D():97-101. PubMed ID: 6761131
    [No Abstract]   [Full Text] [Related]  

  • 24. Hemodynamic effects of calcium-sensitizing agents.
    Vegh A; Papp JG; Udvary E; Kaszala K
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S20-31. PubMed ID: 8907128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy of heart failure. I. Definition, pathophysiology, therapy of acute heart failure].
    Schwinger RH; Erdmann E
    Fortschr Med; 1997 Jun; 115(16):30-4. PubMed ID: 9280746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of pitavastin in Japanese patients with chronic heart failure.
    D'Imperio H; Sanchis J; Núñez E; Núñez J
    Circ J; 2013; 77(8):2204. PubMed ID: 23759657
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of pitavastatin in Japanese patients with chronic heart failure. Reply.
    Takano H
    Circ J; 2013; 77(8):2205. PubMed ID: 23759658
    [No Abstract]   [Full Text] [Related]  

  • 28. Statin therapy in chronic heart failure: frog prince or bare frog?
    Kihara Y
    Circ J; 2013; 77(4):895-7. PubMed ID: 23502989
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hypertension and heart failure. Are there approaches for differential therapy?].
    Böhm M
    MMW Fortschr Med; 2000 Feb; 142(7):31-3. PubMed ID: 10832331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transient dobutamine-mediated pulsus alternans.
    Kahn JH; Starling MR; Supiano MA
    Can J Cardiol; 2001 Feb; 17(2):203-5. PubMed ID: 11223491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inotropic infusions for chronic congestive heart failure: medical miracles or misguided medicinals?
    Ewy GA
    J Am Coll Cardiol; 1999 Feb; 33(2):572-5. PubMed ID: 9973041
    [No Abstract]   [Full Text] [Related]  

  • 32. The force-frequency relation in normal and failing heart.
    Faggiano P; Colucci WS
    Cardiologia; 1996 Dec; 41(12):1155-64. PubMed ID: 9031531
    [No Abstract]   [Full Text] [Related]  

  • 33. [Efficacy and problems of cardiotonic agents viewed from physiopathology of chronic congestive heart failure].
    Asanoi H; Inoue H
    Nihon Naika Gakkai Zasshi; 1995 Sep; 84(9):1465-9. PubMed ID: 8537751
    [No Abstract]   [Full Text] [Related]  

  • 34. Differential alteration of cardiotonic effects of EMD 57033 and beta-adrenoceptor agonists in volume-overload rabbit ventricular myocytes.
    Sugawara H; Sakurai K; Atsumi H; Nakada S; Tomoike H; Endoh M
    J Card Fail; 2000 Dec; 6(4):338-49. PubMed ID: 11145759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Essential basics in therapy of heart failure. Without diuretics the prognosis is poor].
    Bischoff A
    MMW Fortschr Med; 2002 Jul; 144(29-30):6-8. PubMed ID: 12219622
    [No Abstract]   [Full Text] [Related]  

  • 36. Vesnarinone: a new inotropic agent for treating congestive heart failure.
    Cavusoglu E; Frishman WH; Klapholz M
    J Card Fail; 1995 Jun; 1(3):249-57. PubMed ID: 9420657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Consensus of experts on the role of ethyl esters of omega-3 polyunsaturated fatty acids for the treatment and prevention of chronic heart failure (conclusion of experts meeting, June 2011)].
    Belenkov IuN; Mareev VIu; Arutiunov GP; Shliakhto EV; Koziolova NA; Ageev FT; Tatarskiĭ BA; Lopatin IuM; Fomin IV; Kastanian AA; Ardashev AV; Giliarevskiĭ SR; Moiseev SV; Doshitsin VL; Linchak RM;
    Kardiologiia; 2011; 51(9):89-91. PubMed ID: 21943014
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluating the efficacy of new inotropic agents.
    Braunwald E; Colucci WS
    J Am Coll Cardiol; 1984 Jun; 3(6):1570-4. PubMed ID: 6715715
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacologic basis of cardiotonic glucoside therapy].
    Imbs JL
    Cardiology; 1980; 65 Suppl 1():1-8. PubMed ID: 7379062
    [No Abstract]   [Full Text] [Related]  

  • 40. Positive inotropic agents: a double-edged sword for chronic heart failure.
    Asanoi H; Inoue H
    Intern Med; 1996 Jan; 35(1):63-4. PubMed ID: 8652942
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.